The gut microbiota in development and treatment of depression
DOI:
https://doi.org/10.15584/ejcem.2023.4.23Keywords:
depression, gut microbiota, microbiome-gut-brain axis, prebiotics, psychobioticsAbstract
Introduction and aim. Nowadays, almost 4% of people in the world suffer from depressive disorders, and the forecasts of further increase in incidence are alarming. The disease is debilitating and can lead to suicide, and available treatments are still imperfect. The aim of the study was to review the literature and present the potential role of the gut microbiota in the development of depression and to consider the use of prebiotics and probiotics as one of the therapeutic options in this disease.
Material and methods. Review of articles published on PubMed since 2015.
Analysis of the literature. The available reports point to a relationship between disturbances in the composition of the intestinal flora and the development of depressive disorders. In addition, more and more studies indicate the benefits of the influence on mood and clinical improvement, observed when using psychobiotics as an adjuvant treatment of depression, as well as monotherapy.
Conclusion. Further research is needed in this area, especially in humans, to gain a deeper understanding of the role of the gut microbiota in depression and the promising use of psychobiotics for its treatment.
Downloads
References
World Health Organization. Depressive Disorder (Depression). World Health Organisation. https://www.who.int/news-room/fact-sheets/detail/depression. Published March 31, 2023. Accessed July 28, 2023.
Depression – Metaphorical Therapy. https://metaphoricaltherapy.com/problems/depression/. Accessed July 28, 2023.
Dobrek L, Głowacka K. Depression and Its Phytopharmacotherapy- A Narrative Review. Int J Mol Sci. 2023;24(5):4772. doi: 10.3390/ijms24054772
Marwaha S, Palmer E, Suppes T, Cons E, Young AH, Upthegrove R. Novel and emerging treatments for major depression. Lancet. 2023;14;401(10371):141-153. doi: 10.1016/S0140-6736(22)02080-3
Ménard C, Hodes GE, Russo SJ. Pathogenesis of depression: Insights from human and rodent studies. Neuroscience. 2016;321:138-162. doi: 10.1016/j.neuroscience.2015.05.053
Simpson CA, Diaz-Arteche C, Eliby D, Schwartz OS, Simmons JG, Cowan CSM. The gut microbiota in anxiety and depression– A systematic review. Clin Psychol. 2021;83:101943. doi: 10.1016/j.cpr.2020.101943
Munro M, Milne R. Symptoms and causes of depression and its diagnosis and management. Nursing Times. 2020;116:4-18.
Suganya K, Koo BS. Gut–Brain Axis: Role of Gut Microbiota on Neurological Disorders and How Probiotics/Prebiotics Beneficially Modulate Microbial and Immune Pathways to Improve Brain Functions. Int J Mol Sci. 2020;21(20):7551. doi: 10.3390/ijms21207551
Bear TLK, Dalziel JE, Coad J, Roy NC, Butts CA, Gopal PK. The Role of the Gut Microbiota in Dietary Interventions for Depression and Anxiety. Adv Nutr. 2020;11(4):890-907. doi: 10.1093/advances/nmaa016
Liu RT, Walsh RFL, Sheehan AE. Prebiotics and probiotics for depression and anxiety: A systematic review and meta-analysis of controlled clinical trials. Neurosci Biobehav Rev. 2019;102:13-23. doi: 10.1016/j.neubiorev.2019.03.023
Kim S, Jazwinski S Michal. The Gut Microbiota and Healthy Aging: A Mini-Review. Gerontology. 2018;64(6):513-520. doi: 10.1159/000490615
Lynch SV, Pedersen O. The Human Intestinal Microbiome in Health and Disease. Phimister EG, ed. Engl J Med. 2016;375(24):2369-2379. doi: 10.1056/nejmra1600266
Martin CR, Osadchiy V, Kalani A, Mayer EA. The Brain-Gut-Microbiome Axis. CMGH Cell Mol Gastroenterol. 2018;6(2):133-148. doi: 10.1016/j.jcmgh.2018.04.003
Mayer EA. Gut feelings: the emerging biology of gut–brain communication. Na Re Neurosci. 2011;12(8):453-466. doi: 10.1038/nrn3071
Cox LM, Weiner HL. Microbiota Signaling Pathways that Influence Neurologic Disease. Neurotherapeutics. 2018;15(1):135-145. doi: 10.1007/s13311-017-0598-8
Heiss CN, Olofsson LE. The role of the gut microbiota in development, function and disorders of the central nervous system and the enteric nervous system. J Neuroendocrinol. 2019;31(5):e12684. doi: 10.1111/jne.12684
Yuan N, Chen Y, Xia Y, Dai J, Liu C. Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses. Transl Psychiatry. 2019;9(1):233. doi: 10.1038/s41398-019-0570-y
Auteri M, Zizzo MG, Serio R. GABA and GABA receptors in the gastrointestinal tract: from motility to inflammation. Pharmacol Res. 2015;93:11-21. doi: 10.1016/j.phrs.2014.12.001
Israelyan N, Del Colle A, Li Z, et al. Effects of Serotonin and Slow-Release 5-Hydroxytryptophan on Gastrointestinal Motility in a Mouse Model of Depression. Gastroenterology. 2019;157(2):507-521.e4. doi: 10.1053/j.gastro.2019.04.022
Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell. 2016;165(6):1332-1345. doi: 10.1016/j.cell.2016.05.041
Correia AS, Vale N. Tryptophan Metabolism in Depression: A Narrative Review with a Focus on Serotonin and Kynurenine Pathways. Int. J Mol. Sci. 2022;23(15):8493. doi: 10.3390/ijms23158493
Aarsland TIM, Instanes JT, Posserud MBR, Ulvik A, Kessler U, Haavik J. Changes in Tryptophan-Kynurenine Metabolism in Patients with Depression Undergoing ECT—A Systematic Review. Pharmaceuticals. 2022;15(11):1439. doi: 10.3390/ph15111439
Winter G, Hart RA, Charlesworth RPG, Sharpley CF. Gut Microbiome and Depression: What We Know and What We Need to Know. Reviews in the neurosciences. Rev Neurosci. 2018;29(6):629-643. doi: 10.1515/revneuro-2017-0072.
Trzeciak P, Herbet M. Role of the Intestinal Microbiome, Intestinal Barrier and Psychobiotics in Depression. Nutrients. 2021;13(3):927. doi: 10.3390/nu13030927
Du Y, Gao XR, Peng L, Ge JF. Crosstalk between the microbiota-gut-brain axis and depression. Heliyon. 2020;6(6):e04097. doi: 10.1016/j.heliyon.2020.e04097
Tyler Patterson T, Grandhi R. Gut Microbiota and Neurologic Diseases and Injuries. Adv Exp Med Biol. 2020;1238:73-91. doi: 10.1007/978-981-15-2385-4_6
Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid–induced insulin resistance. J Clin Invest. 2006;116(11):3015-3025. doi: 10.1172/jci28898
Chang L, Wei Y, Hashimoto K. Brain–gut–microbiota axis in depression: A historical overview and future directions. Brain Res Bull. 2022;182:44-56. doi: 10.1016/j.brainresbull.2022.02.004
Van de Wouw M, Boehme M, Lyte JM, et al. Short-chain fatty acids: microbial metabolites that alleviate stress-induced brain-gut axis alterations. J Physiol. 2018;596(20):4923-4944. doi: 10.1113/jp276431
Peirce JM, Alviña K. The role of inflammation and the gut microbiome in depression and anxiety. J Neurosci Res. 2019;97(10):1223-1241. doi: 10.1002/jnr.24476
Capuco A, Urits I, Hasoon J, et al. Current Perspectives on Gut Microbiome Dysbiosis and Depression. Adv Ther. 2020;37(4):1328-1346. doi: 10.1007/s12325-020-01272-7
Chen Z, Li J, Gui S, et al. Comparative metaproteomics analysis shows altered fecal microbiota signatures in patients with major depressive disorder. NeuroReport. 2018;29(5):417-425. doi: 10.1097/wnr.0000000000000985
Chung YE, Chen HC, Chou HL, et al. Exploration of microbiota targets for major depressive disorder and mood related traits. J Psychiatr Res. 2019;111:74-82. doi: 10.1016/j.jpsychires.2019.01.016
Jiang H, Ling Z, Zhang Y, et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun. 2015;48:186-194. doi: 10.1016/j.bbi.2015.03.016
Kelly JR, Borre Y, O’ Brien C, et al. Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. J Psychiatr Res. 2016;82:109-118. doi: 10.1016/j.jpsychires.2016.07.019
Sonali S, Ray B, Ahmed Tousif H, et al. Mechanistic Insights into the Link between Gut Dysbiosis and Major Depression: An Extensive Review. Cells. 2022;11(8):1362. doi: 10.3390/cells11081362
Młynarska E, Gadzinowska J, Tokarek J, et al. The Role of the Microbiome-Brain-Gut Axis in the Pathogenesis of Depressive Disorder. Nutrients. 2022;14(9):1921. doi: 10.3390/nu14091921
Yuan X, Chen B, Duan Z, et al. Depression and anxiety in patients with active ulcerative colitis: crosstalk of gut microbiota, metabolomics and proteomics. Gut Microbes. 2021;13(1). doi: 10.1080/19490976.2021.1987779
Klimova B, Novotny M, Valis M. The Impact of Nutrition and Intestinal Microbiome on Elderly Depression—A Systematic Review. Nutrients. 2020;12(3):710. doi: 10.3390/nu12030710
Li D, Sun T, Tong Y, et al. Gut-microbiome-expressed 3β-hydroxysteroid dehydrogenase degrades estradiol and is linked to depression in premenopausal females. Cell Metab. 2023;4;35(4):685-694.e5. doi: 10.1016/j.cmet.2023.02.017
Chudzik A, Orzyłowska A, Rola R, Stanisz GJ. Probiotics, Prebiotics and Postbiotics on Mitigation of Depression Symptoms: Modulation of the Brain–Gut–Microbiome Axis. Biomolecules. 2021;11(7):1000. doi: 10.3390/biom11071000
Kazemi A, Noorbala AA, Azam K, Eskandari MH, Djafarian K. Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: A randomized clinical trial. Clin Nutr. 2019;38(2):522-528. doi: 10.1016/j.clnu.2018.04.010
Heidarzadeh-Rad N, Gökmen-Özel H, Kazemi A, Almasi N, Djafarian K. Effects of a Psychobiotic Supplement on Serum Brain-derived Neurotrophic Factor Levels in Depressive Patients: A Post Hoc Analysis of a Randomized Clinical Trial. Clin Neuropharmacol. 2020;26(4):486-495. doi: 10.5056/jnm20079
Miyaoka T, Kanayama M, Wake R, et al. Clostridium butyricum MIYAIRI 588 as Adjunctive Therapy for Treatment-Resistant Major Depressive Disorder: A Prospective Open-Label Trial. Clinical Neuropharmacology. 2018;41(5):151-155. doi: 10.1097/wnf.0000000000000299
Rudzki L, Ostrowska L, Pawlak D, et al. Probiotic Lactobacillus Plantarum 299v decreases kynurenine concentration and improves cognitive functions in patients with major depression: A double-blind, randomized, placebo controlled study. Psychoneuroendocrinology. 2019;100:213-222. doi: 10.1016/j.psyneuen.2018.10.010
Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M, et al. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. Nutrition. 2016; 32(3): 315-320. doi:10.1016/j.nut.2015.09.003
Otaka M, Kikuchi-Hayakawa H, Ogura, J, et al. Effect of Lacticaseibacillus paracasei strain shirota on improvement in depressive symptoms, and its association with abundance of actinobacteria in gut microbiota. Microorganisms. 2021;9(5):1026. doi: 10.3390/microorganisms9051026
Wallace CJK, Milev RV. The Efficacy, Safety, and Tolerability of Probiotics on Depression: Clinical Results From an Open-Label Pilot Study. Front Psychiatry. 2021;15;12:618279 doi: 10.3389/fpsyt.2021.618279
Chahwan B, Kwan S, Isik A, van Hemert S, Burke C, Roberts L. Gut feelings: A randomised, triple-blind, placebo-controlled trial of probiotics for depressive symptoms. J Affect Disord. 2019;253:317-326. doi: 10.1016/j.jad.2019.04.097
Reininghaus EZ, Platzer M, Kohlhammer-Dohr A, et al. PROVIT: Supplementary Probiotic Treatment and Vitamin B7 in Depression—A Randomized Controlled Trial. Nutrients. 2020;12(11):3422. doi: 10.3390/nu12113422
Alli SR, Gorbovskaya I, Liu JCW, Kolla NJ, Brown L, Müller DJ. The Gut Microbiome in Depression and Potential Benefit of Prebiotics, Probiotics and Synbiotics: A Systematic Review of Clinical Trials and Observational Studies. Int J Mol Sci. 2022;23(9):4494. doi: 10.3390/ijms23094494
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
